PLAT and COVID-19: Given the histological finding of widespread fibrin deposition consistent with microvascular thrombosis reported in COVID‐19 cases,76 clinical trials are needed to evaluate the efficacy of experimental fibrinolytic therapies such as tissue plasminogen activator.77